ArticleEpilepsia open2026
MiR-30a-5p mediates epileptogenesis in epilepsy models by targeting SOX4 to regulate the Wnt/β-catenin pathway.
Article in Epilepsia open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThe pathogenesis of epilepsy is closely associated with neuronal synaptic plasticity. MicroRNAs (miRNAs) can regulate various biological processes by binding to specific sequences on target genes. This study employs bioinformatics, molecular dynamics, and experimental approaches to investigate the mechanism by which MiR-30a-5p treats epilepsy through targeting SOX4 and regulating the Wnt/β-catenin signaling pathway.
methodsPerformed bioinformatics analysis to predict the signaling pathways involved in miRNA-30a-5p-mediated intervention in epilepsy. RT-qPCR was used to detect the expression levels of miR-30a-5p in the hippocampal tissues of epileptic rats and in primary hippocampal neurons subjected to Mg
resultsThe expression level of miR-30a-5p was significantly elevated in the hippocampal region of epileptic rats and in magnesium-depleted hippocampal neuronal cultures. SOX4 was identified as a direct target of miR-30a-5p. Inhibiting miR-30a-5p reduces the expression of synapse-associated proteins (SYP/CaMKII/PSD95), while upregulating SOX4 and downregulating the levels of Wnt3a, β-catenin, and cyclin D1. miR-30a-5p may participate in alterations of neuronal synaptic plasticity by directly targeting and inhibiting SOX4 expression, thereby activating the Wnt/β-catenin signaling pathway. SIGNIFICANCE: This study provides evidence that miR-30a-5p participates in the process of synaptic plasticity impairment in epileptic neurons. The study confirms a direct interaction between miR-30a-5p and SOX4. Furthermore, miR-30a-5p regulates the Wnt/β-catenin signaling pathway by targeting SOX4, thereby influencing neuronal synaptic plasticity impairment. This discovery provides a novel potential therapeutic target for delaying epilepsy progression. PLAIN LANGUAGE SUMMARY: Epilepsy is a common brain disorder that affects millions of people worldwide. This study found that a small molecule called miR-30a-5p increases in the brain during epilepsy and disrupts normal communication between neurons. By blocking this molecule in laboratory experiments, we were able to improve neuron function and reduce damage. These findings suggest that targeting miR-30a-5p could lead to new treatments to slow down the progression of epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.